Koeberle, Dieter; Montemurro, Michael; Samaras, Panagiotis; Majno, Pietro; Simcock, Mathew; Limacher, Andreas; Lerch, Stefanie; Kovàcs, Katalin; Inauen, Roman; Hess, Vivianne; Saletti, Piercarlo; Borner, Markus; Roth, Arnaud; Bodoky, György (2010). Continuous Sunitinib treatment in patients with advanced hepatocellular carcinoma: a Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) multicenter phase II trial (SAKK 77/06). Oncologist, 15(3), pp. 285-92. Miamisburg, Ohio: AlphaMed Press 10.1634/theoncologist.2009-0316
Full text not available from this repository. (Request a copy)Sunitinib (SU) is a multitargeted tyrosine kinase inhibitor with antitumor and antiangiogenic activity. The objective of this trial was to demonstrate antitumor activity of continuous SU treatment in patients with hepatocellular carcinoma (HCC).
Item Type: |
Journal Article (Original Article) |
|---|---|
Division/Institute: |
04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Medical Oncology |
UniBE Contributor: |
Borner, Markus |
ISSN: |
1083-7159 |
Publisher: |
AlphaMed Press |
Language: |
English |
Submitter: |
Factscience Import |
Date Deposited: |
04 Oct 2013 14:09 |
Last Modified: |
05 Dec 2022 14:00 |
Publisher DOI: |
10.1634/theoncologist.2009-0316 |
PubMed ID: |
20203173 |
Web of Science ID: |
000275998400007 |
URI: |
https://boris.unibe.ch/id/eprint/1083 (FactScience: 201830) |
Actions (login required)
 |
Edit item |